CONMED Co. (CNMD) Sees Strong Trading Volume on Insider Buying Activity

By Maddie Sorenson

CONMED Co. (NASDAQ:CNMD) saw unusually-strong trading volume on Tuesday after an insider bought additional shares in the company, AnalystRatings.NETreports. Approximately 186,641 shares were traded during mid-day trading, an increase of 18% from the previous session’s volume of 157,795 shares.The stock last traded at $41.79 and had previously closed at $40.85.

Specifically, Director David M. Bronson acquired 1,500 shares of CONMED stock in a transaction that occurred on Friday, December 11th. The stock was purchased at an average price of $41.01 per share, for a total transaction of $61,515.00. Following the completion of the transaction, the director now directly owns 1,500 shares in the company, valued at $61,515. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of brokerages have recently weighed in on CNMD. Needham & Company LLC reaffirmed a “buy” rating on shares of CONMED in a research note on Monday, November 16th. Leerink Swann reaffirmed a “buy” rating on shares of CONMED in a research note on Monday, November 16th. Deutsche Bank reiterated a “buy” rating on shares of CONMED in a report on Tuesday, November 17th. Zacks Investment Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a report on Thursday, November 19th. Finally, Piper Jaffray reiterated a “neutral” rating and issued a $51.00 target price on shares of CONMED in a report on Thursday, August 27th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $55.50.

READ MORE HERE

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use